|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
|
US6743427B1
(en)
|
1997-12-02 |
2004-06-01 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
|
US7179892B2
(en)
*
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
|
US20080050367A1
(en)
*
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
|
US6787523B1
(en)
*
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
|
US6761888B1
(en)
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
|
US7964192B1
(en)
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
|
US6923964B1
(en)
|
1997-12-02 |
2005-08-02 |
Neuralab Limited |
Active immunization of AScr for prion disorders
|
|
US6750324B1
(en)
|
1997-12-02 |
2004-06-15 |
Neuralab Limited |
Humanized and chimeric N-terminal amyloid beta-antibodies
|
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
|
US20050059802A1
(en)
*
|
1998-04-07 |
2005-03-17 |
Neuralab Ltd |
Prevention and treatment of amyloidogenic disease
|
|
US20030147882A1
(en)
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
|
UA81216C2
(en)
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
|
WO2000077178A1
(en)
|
1999-06-16 |
2000-12-21 |
Boston Biomedical Research Institute |
IMMUNOLOGICAL CONTROL OF β-AMYLOID LEVELS IN VIVO
|
|
SI1257584T2
(sl)
|
2000-02-24 |
2013-07-31 |
Washington University St. Louis |
Humanizirana protitelesa, ki veĹľejo amiloidni peptid beta
|
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
|
TWI255272B
(en)
|
2000-12-06 |
2006-05-21 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
|
ES2437875T3
(es)
*
|
2001-04-30 |
2014-01-14 |
Eli Lilly And Company |
Anticuerpos humanizados que reconocen el péptido beta-amiloide
|
|
AU2002257162A1
(en)
*
|
2001-04-30 |
2002-11-11 |
Eli Lilly And Company |
Humanized antibodies
|
|
US20020197258A1
(en)
*
|
2001-06-22 |
2002-12-26 |
Ghanbari Hossein A. |
Compositions and methods for preventing protein aggregation in neurodegenerative diseases
|
|
EP1420032B2
(en)
†
|
2001-08-03 |
2015-12-16 |
Medical & Biological Laboratories Co., Ltd. |
Antibody recognizing gm1 ganglioside-bound amyloid beta-protein and dna encoding the antibody
|
|
ES2295401T3
(es)
*
|
2001-08-17 |
2008-04-16 |
Washington University |
Metodo de ensayo para la enfermedad de alzheimer.
|
|
US20040241164A1
(en)
*
|
2001-08-17 |
2004-12-02 |
Bales Kelly Renee |
Use of antibodies having high affinity for soluble ab to treat conditions and diseases related to ass
|
|
US20040192898A1
(en)
*
|
2001-08-17 |
2004-09-30 |
Jia Audrey Yunhua |
Anti-abeta antibodies
|
|
AU2002324468A1
(en)
*
|
2001-08-17 |
2003-03-03 |
Eli Lilly And Company |
Rapid improvement of cognition in conditions related to abeta
|
|
PT1944040E
(pt)
*
|
2001-08-17 |
2012-10-31 |
Univ Washington |
Método de avaliação para a doença de alzheimer
|
|
US7179606B2
(en)
*
|
2001-11-23 |
2007-02-20 |
Syn X Pharma, Inc. |
IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease
|
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
CA2483729A1
(en)
*
|
2002-04-25 |
2003-11-06 |
Eli Lilly And Company |
Method for treating anxiety and mood disorders in older subjects
|
|
WO2004029629A1
(en)
|
2002-09-27 |
2004-04-08 |
Janssen Pharmaceutica N.V. |
N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses
|
|
FR2846667B1
(fr)
*
|
2002-11-06 |
2004-12-31 |
Pasteur Institut |
Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
|
|
WO2004056318A2
(en)
|
2002-12-19 |
2004-07-08 |
New York University |
Method for treating amyloid disease
|
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
|
PL378571A1
(pl)
*
|
2003-02-01 |
2006-05-02 |
Neuralab Limited |
Czynna immunizacja dla wytworzenia przeciwciał przeciw rozpuszczalnemu A-ß
|
|
WO2004071408A2
(en)
|
2003-02-10 |
2004-08-26 |
Applied Molecular Evolution, Inc. |
Aβ BINDING MOLECULES
|
|
US8663650B2
(en)
|
2003-02-21 |
2014-03-04 |
Ac Immune Sa |
Methods and compositions comprising supramolecular constructs
|
|
US7732162B2
(en)
|
2003-05-05 |
2010-06-08 |
Probiodrug Ag |
Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
|
|
TWI374893B
(en)
*
|
2003-05-30 |
2012-10-21 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
|
EP3679951A1
(en)
|
2003-06-27 |
2020-07-15 |
Amgen Fremont Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
|
AT413336B
(de)
|
2003-09-12 |
2006-02-15 |
Mattner Frank Dr |
Apherese-vorrichtung
|
|
KR101139103B1
(ko)
*
|
2003-09-12 |
2012-07-05 |
아피리스 아게 |
아페레시스 장치
|
|
US7848543B2
(en)
*
|
2004-02-05 |
2010-12-07 |
Brainlab Ag |
Method and system for prediction and management of material and information transport in an organism
|
|
ES2375627T3
(es)
*
|
2004-02-23 |
2012-03-02 |
Eli Lilly And Company |
Anticuerpos anti-abeta.
|
|
CA2564432A1
(en)
*
|
2004-04-27 |
2005-11-10 |
Juridical Foundation The Chemo-Sero-Therapeutic Research Institute |
Human anti-amyloid .beta. peptide antibody and fragment of said antibody
|
|
WO2006014478A1
(en)
*
|
2004-07-02 |
2006-02-09 |
Northwestern University |
MONOLOCAL ANTIBODIES THAT TARGET PATHOLOGICAL ASSEMBLIES OF AMYLOID β (ABETA)
|
|
US20060024667A1
(en)
|
2004-07-29 |
2006-02-02 |
Karen Manucharyan |
Compositions and methods for Alzheimer's disease
|
|
CN101027391A
(zh)
*
|
2004-10-05 |
2007-08-29 |
惠氏公司 |
用于改善重组蛋白质产生的方法和组合物
|
|
US9907485B2
(en)
*
|
2004-10-15 |
2018-03-06 |
Brainlab Ag |
Targeted immunization and plaque destruction against Alzheimer's disease
|
|
US9924888B2
(en)
*
|
2004-10-15 |
2018-03-27 |
Brainlab Ag |
Targeted infusion of agents against parkinson's disease
|
|
US9901413B2
(en)
*
|
2004-10-15 |
2018-02-27 |
Brainlab Ag |
Targeted infusion of agents for treatment of ALS
|
|
TW200635607A
(en)
*
|
2004-12-15 |
2006-10-16 |
Elan Pharm Inc |
Humanized Aβ antibodies for use in improving cognition
|
|
EP1838349A1
(en)
*
|
2004-12-15 |
2007-10-03 |
Neuralab, Ltd. |
Amyloid beta antibodies for use in improving cognition
|
|
WO2006066049A2
(en)
*
|
2004-12-15 |
2006-06-22 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
|
US20090074775A1
(en)
*
|
2004-12-22 |
2009-03-19 |
David Michael Holtzman |
Use Of Anti-AB Antibody To Treat Traumatic Brain Injury
|
|
EP1841455A1
(en)
*
|
2005-01-24 |
2007-10-10 |
Amgen Inc. |
Humanized anti-amyloid antibody
|
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
|
EP1896504B1
(en)
|
2005-06-17 |
2012-11-21 |
Wyeth LLC |
Methods of purifying fc region containing antibodies
|
|
PT1976877E
(pt)
*
|
2005-11-30 |
2014-04-29 |
Abbvie Inc |
Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações
|
|
CN117903302A
(zh)
|
2005-11-30 |
2024-04-19 |
Abbvie 公司 |
抗-Aβ球聚体抗体，其相关产品，生产所述抗体的方法，所述抗体的应用以及使用方法
|
|
AR057233A1
(es)
|
2005-12-12 |
2007-11-21 |
Hoffmann La Roche |
Glicosilacion en la region variable
|
|
ES2454253T3
(es)
*
|
2005-12-12 |
2014-04-10 |
Ac Immune S.A. |
Anticuerpos monoclonales específicos de beta A 1-42 con propiedades terapéuticas
|
|
DE602007003703D1
(de)
*
|
2006-03-30 |
2010-01-21 |
Glaxo Group Ltd |
Gegen amyloid-beta peptid gerichtete antikörper
|
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
|
CN101058608B
(zh)
*
|
2006-04-21 |
2011-02-23 |
杜如昱 |
人类抗Aβ1-32淀粉样蛋白抗体、其纯化方法及用途
|
|
CN103524617B
(zh)
*
|
2006-07-14 |
2016-12-28 |
Ac免疫有限公司 |
针对淀粉状蛋白β的人源化抗体
|
|
KR101605207B1
(ko)
*
|
2006-07-14 |
2016-03-22 |
에이씨 이뮨 에스.에이. |
아밀로이드 베타에 대해 인간화된 항체
|
|
NO348280B1
(no)
*
|
2006-07-14 |
2024-11-04 |
Genentech Inc |
Humanisert antistoff
|
|
EP3988566A1
(en)
*
|
2006-07-14 |
2022-04-27 |
AC Immune SA |
Humanized antibody against amyloid beta
|
|
SI2074145T1
(sl)
*
|
2006-10-02 |
2017-12-29 |
Ac Immune S.A. |
Humanizirano protitelo proti amiloid beta
|
|
JP2010506839A
(ja)
|
2006-10-12 |
2010-03-04 |
ワイス エルエルシー |
乳光の低減を伴う方法および組成物
|
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
|
US7939075B2
(en)
|
2007-01-11 |
2011-05-10 |
Philipps-Universitaet Marburg |
Human monoclonal anti-amyloid-beta antibodies
|
|
KR101160385B1
(ko)
|
2007-01-18 |
2012-07-10 |
일라이 릴리 앤드 캄파니 |
페길화된 Ａβ ＦＡＢ
|
|
CA2676715A1
(en)
|
2007-02-12 |
2008-08-21 |
Merck & Co., Inc. |
Piperazine derivatives for treatment of ad and related conditions
|
|
US20100311767A1
(en)
|
2007-02-27 |
2010-12-09 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
|
ZA200905537B
(en)
|
2007-03-01 |
2010-10-27 |
Probiodrug Ag |
New use of glutaminyl cyclase inhibitors
|
|
EP2865670B1
(en)
|
2007-04-18 |
2017-01-11 |
Probiodrug AG |
Thiourea derivatives as glutaminyl cyclase inhibitors
|
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
|
CN101970000A
(zh)
*
|
2007-04-18 |
2011-02-09 |
杨森阿尔茨海默氏症免疫治疗公司 |
脑淀粉样血管病的预防和治疗
|
|
US9265577B2
(en)
|
2007-05-18 |
2016-02-23 |
The Johns Hopkins University |
Methods and systems for providing planning and dispensation of research and/or treatment for brain disease
|
|
US20090232801A1
(en)
*
|
2007-05-30 |
2009-09-17 |
Abbot Laboratories |
Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
|
|
JP2010528583A
(ja)
*
|
2007-06-11 |
2010-08-26 |
エーシー イミューン ソシエテ アノニム |
アミロイドβに対するヒト化抗体
|
|
PL2170389T3
(pl)
*
|
2007-06-12 |
2015-03-31 |
Ac Immune Sa |
Humanizowane przeciwciało przeciw amyloidowi beta
|
|
US8613923B2
(en)
|
2007-06-12 |
2013-12-24 |
Ac Immune S.A. |
Monoclonal antibody
|
|
DK2182983T3
(da)
|
2007-07-27 |
2014-07-14 |
Janssen Alzheimer Immunotherap |
Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
|
|
SG188136A1
(en)
*
|
2007-09-13 |
2013-03-28 |
Delenex Therapeutics Ag |
HUMANIZED ANTIBODIES AGAINST THE ß-AMYLOYD PEPTIDE
|
|
CN105169388A
(zh)
*
|
2007-10-05 |
2015-12-23 |
基因技术公司 |
人源化抗体
|
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
|
KR101581733B1
(ko)
*
|
2007-11-16 |
2015-12-31 |
더 락커펠러 유니버시티 |
원섬유 형태의 베타아밀로이드 단백질에 대해 특이적인 항체
|
|
WO2009085200A2
(en)
|
2007-12-21 |
2009-07-09 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
|
EP2106802A1
(en)
|
2008-04-02 |
2009-10-07 |
SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. |
Modified peptides as synthetic vaccines in amyloid-associated disease
|
|
EP2149380A1
(en)
*
|
2008-07-29 |
2010-02-03 |
Medivet Pharma, S.L. |
Veterinary immunotherapy compositions for the Aged Related Cognitive Dysfunction.
|
|
US8815794B2
(en)
|
2008-08-28 |
2014-08-26 |
The Research Foundation For The State University Of New York |
Treatment of amyloidoses using myelin basic protein and fragments thereof
|
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
|
US8614297B2
(en)
*
|
2008-12-22 |
2013-12-24 |
Hoffmann-La Roche Inc. |
Anti-idiotype antibody against an antibody against the amyloid β peptide
|
|
EP2475428B1
(en)
|
2009-09-11 |
2015-07-01 |
Probiodrug AG |
Heterocylcic derivatives as inhibitors of glutaminyl cyclase
|
|
DK2510359T3
(en)
|
2009-12-11 |
2015-12-07 |
Araclón Biotech S L |
METHODS AND REAGENTS FOR IMPROVED DETECTION OF AMYLOID-BETA PEPTIDES
|
|
CA2791648A1
(en)
|
2010-03-01 |
2011-09-09 |
The J. David Gladstone Institutes |
Antibody specific for apolipoprotein and methods of use thereof
|
|
WO2011107530A2
(en)
|
2010-03-03 |
2011-09-09 |
Probiodrug Ag |
Novel inhibitors
|
|
BR112012022478B1
(pt)
|
2010-03-10 |
2021-09-21 |
Probiodrug Ag |
Inibidores heterocíclicos de glutaminil ciclase (qc, ec 2.3.2.5), seu processo de preparação, e composição farmacêutica
|
|
CN104744591B
(zh)
|
2010-04-15 |
2022-09-27 |
Abbvie德国有限责任两合公司 |
β淀粉样蛋白结合蛋白
|
|
JP5945532B2
(ja)
|
2010-04-21 |
2016-07-05 |
プロビオドルグ エージー |
グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
|
|
WO2011149461A1
(en)
|
2010-05-27 |
2011-12-01 |
Medtronic, Inc. |
Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
|
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
|
EP3533803B1
(en)
|
2010-08-14 |
2021-10-27 |
AbbVie Inc. |
Anti-amyloid-beta antibodies
|
|
CN103429606A
(zh)
|
2010-10-01 |
2013-12-04 |
现代治疗公司 |
设计核酸及其使用方法
|
|
ES2570167T3
(es)
|
2011-03-16 |
2016-05-17 |
Probiodrug Ag |
Derivados de benzimidazol como inhibidores de glutaminil ciclasa
|
|
CA2831613A1
(en)
|
2011-03-31 |
2012-10-04 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
|
ES2602794T3
(es)
|
2011-03-31 |
2017-02-22 |
Pfizer Inc |
Piridinonas bicíclicas novedosas
|
|
EP2511296A1
(en)
|
2011-04-12 |
2012-10-17 |
Araclón Biotech, S. L. |
Antibody, kit and method for determination of amyloid peptides
|
|
WO2012172449A1
(en)
|
2011-06-13 |
2012-12-20 |
Pfizer Inc. |
Lactams as beta secretase inhibitors
|
|
WO2013030713A1
(en)
|
2011-08-31 |
2013-03-07 |
Pfizer Inc. |
Hexahydropyrano [3,4-d][1,3] thiazin-2-amine compounds
|
|
JP2012050437A
(ja)
*
|
2011-09-12 |
2012-03-15 |
Janssen Alzheimer Immunotherapy |
ベータアミロイドペプチドを認識するヒト化抗体
|
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
KR20190099538A
(ko)
|
2011-10-03 |
2019-08-27 |
모더나 세라퓨틱스, 인코포레이티드 |
변형된 뉴클레오사이드, 뉴클레오타이드, 및 핵산, 및 이들의 용도
|
|
EP4144378A1
(en)
|
2011-12-16 |
2023-03-08 |
ModernaTX, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
SG10201805622QA
(en)
*
|
2011-12-22 |
2018-08-30 |
Hoffmann La Roche |
Expression Vector Organization, Novel Production Cell Generation Methods And Their Use For The Recombinant Production Of Polypeptides
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
AU2013243954A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
|
WO2013164730A1
(en)
|
2012-05-04 |
2013-11-07 |
Pfizer Inc. |
Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin- 2 -amine compounds as inhibitors of app, bace1 and bace 2.
|
|
CA2878054C
(en)
|
2012-06-29 |
2018-09-11 |
Pfizer Inc. |
Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
|
|
HK1208810A1
(en)
*
|
2012-07-03 |
2016-03-18 |
Janssen Alzheimer Immunotherapy |
C-terminal and central epitope a-beta antibodies
|
|
US9260455B2
(en)
|
2012-09-20 |
2016-02-16 |
Pfizer Inc. |
Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
|
UA110688C2
(uk)
|
2012-09-21 |
2016-01-25 |
Пфайзер Інк. |
Біциклічні піридинони
|
|
DK2922554T3
(en)
|
2012-11-26 |
2022-05-23 |
Modernatx Inc |
Terminalt modificeret rna
|
|
WO2014091352A1
(en)
|
2012-12-11 |
2014-06-19 |
Pfizer Inc. |
Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
|
|
WO2014097038A1
(en)
|
2012-12-19 |
2014-06-26 |
Pfizer Inc. |
CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
|
|
EP2956458B1
(en)
|
2013-02-13 |
2017-08-09 |
Pfizer Inc |
Heteroaryl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
|
US9233981B1
(en)
|
2013-02-15 |
2016-01-12 |
Pfizer Inc. |
Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
|
|
BR112015019276A2
(pt)
|
2013-02-19 |
2017-07-18 |
Pfizer |
compostos de azabenzimidazol como inibidores de isoenzimas de pde4 para o tratamento de distúrbios do snc e outros distúrbios
|
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
|
HRP20240107T1
(hr)
|
2013-05-20 |
2024-04-12 |
F. Hoffmann - La Roche Ag |
Protutijela na transferinski receptor i postupci uporabe
|
|
CA3174012A1
(en)
|
2013-09-13 |
2015-03-19 |
Genentech, Inc. |
Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
|
|
IL244149B2
(en)
|
2013-09-13 |
2025-09-01 |
Genentech Inc |
Methods and compositions containing purified recombinant polypeptides
|
|
US10023626B2
(en)
|
2013-09-30 |
2018-07-17 |
Modernatx, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
BR112016007255A2
(pt)
|
2013-10-03 |
2017-09-12 |
Moderna Therapeutics Inc |
polinucleotídeos que codificam receptor de lipoproteína de baixa densidade
|
|
WO2015049616A1
(en)
|
2013-10-04 |
2015-04-09 |
Pfizer Inc. |
Novel bicyclic pyridinones as gamma-secretase modulators
|
|
JP6487921B2
(ja)
|
2013-12-17 |
2019-03-20 |
ファイザー・インク |
ＬＲＲＫ２阻害薬としての新規の３，４−二置換−１Ｈ−ピロロ［２，３−ｂ］ピリジンおよび４，５−二置換−７Ｈ−ピロロ［２，３−ｃ］ピリダジン
|
|
WO2015150957A1
(en)
|
2014-04-01 |
2015-10-08 |
Pfizer Inc. |
Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
|
|
AP2016009493A0
(en)
|
2014-04-10 |
2016-10-31 |
Pfizer |
2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
|
|
WO2015165961A1
(en)
|
2014-04-29 |
2015-11-05 |
Affiris Ag |
Treatment and prevention of alzheimer's disease (ad)
|
|
US10131669B2
(en)
|
2014-07-24 |
2018-11-20 |
Pfizer Inc. |
Pyrazolopyrimidine compounds
|
|
EA031201B1
(ru)
|
2014-08-06 |
2018-11-30 |
Пфайзер Инк. |
Соединения имидазопиридазина
|
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
|
CN107428820B
(zh)
|
2014-11-19 |
2022-03-22 |
阿克松神经系统科学公司 |
在阿尔茨海默氏病中的人源化tau抗体
|
|
JP6993228B2
(ja)
|
2014-11-19 |
2022-03-03 |
ジェネンテック， インコーポレイテッド |
抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
|
|
WO2016125048A1
(en)
|
2015-02-03 |
2016-08-11 |
Pfizer Inc. |
Novel cyclopropabenzofuranyl pyridopyrazinediones
|
|
ES2924371T3
(es)
|
2015-06-17 |
2022-10-06 |
Pfizer |
Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
|
|
JP2018522891A
(ja)
*
|
2015-07-21 |
2018-08-16 |
バイオアークティック アーベー |
凝集ペプチドを標的とする外傷性脳損傷の治療方法
|
|
WO2017046675A1
(en)
|
2015-09-14 |
2017-03-23 |
Pfizer Inc. |
Novel imidazo [4,5-c] quinoline and imidazo [4,5-c][1,5] naphthyridine derivatives as lrrk2 inhibitors
|
|
WO2017051294A1
(en)
|
2015-09-24 |
2017-03-30 |
Pfizer Inc. |
N-[2-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2h-1,2,4-thiadiazin-5-yl)-1,3-thiazol-4-yl] amides useful as bace inhibitors
|
|
BR112018003489A2
(pt)
|
2015-09-24 |
2018-09-25 |
Pfizer |
n-[2-(2-amino-6,6-dissubstituído-4,4a,5,6-tetra-hidropirano[3,4-d][1,3]tiazin-8a(8h)-il)-1,3-tiazol-4-il]amidas
|
|
EP3353182A1
(en)
|
2015-09-24 |
2018-08-01 |
Pfizer Inc |
Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
|
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
|
JP2019501115A
(ja)
|
2015-10-28 |
2019-01-17 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
遺伝子治療のためのアデノ随伴ウイルスベクターのくも膜下腔内投与
|
|
AU2016354688B2
(en)
|
2015-11-09 |
2021-12-16 |
The University Of British Columbia |
Epitopes in Amyloid beta mid-region and conformationally-selective antibodies thereto
|
|
EP3374379A4
(en)
|
2015-11-09 |
2019-05-15 |
The University Of British Columbia |
N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATION-SELECTIVE ANTIBODIES
|
|
HK1259324A1
(zh)
|
2015-11-09 |
2019-11-29 |
英属哥伦比亚大学 |
淀粉样蛋白β表位及其抗体
|
|
BR112018015191B1
(pt)
|
2016-02-23 |
2023-10-17 |
Pfizer Inc |
Compostos de 6,7-di-hidro-5h-pirazolo[5,1-b][1,3]oxazina-2-carboxamida, seu uso e composição farmacêutica que os compreende
|
|
DK3478679T3
(da)
|
2016-07-01 |
2021-06-21 |
Pfizer |
5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme
|
|
TWI735600B
(zh)
|
2016-07-01 |
2021-08-11 |
美商美國禮來大藥廠 |
抗－N3pGlu類澱粉β肽抗體及其用途
|
|
KR102550991B1
(ko)
|
2016-07-18 |
2023-07-04 |
더 유니버시티 오브 브리티쉬 콜롬비아 |
아밀로이드 베타에 대한 항체
|
|
WO2018031361A2
(en)
|
2016-08-09 |
2018-02-15 |
Eli Lilly And Company |
Combination therapy
|
|
JP7730008B2
(ja)
|
2016-09-27 |
2025-08-27 |
セロ・セラピューティクス・ホールディングス・インコーポレイテッド |
キメラエンガルフメント受容体分子
|
|
AU2017350947B2
(en)
|
2016-10-28 |
2024-02-15 |
Washington University |
Anti-ApoE antibodies
|
|
US20180125920A1
(en)
|
2016-11-09 |
2018-05-10 |
The University Of British Columbia |
Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
|
|
EP3592741B1
(en)
|
2017-03-10 |
2023-02-15 |
Pfizer Inc. |
Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
|
|
IL269215B
(en)
|
2017-03-10 |
2022-09-01 |
Pfizer |
Disubstituted imidazole[4,5-c]quinoline derivatives
|
|
JOP20190247A1
(ar)
*
|
2017-04-20 |
2019-10-20 |
Lilly Co Eli |
أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
|
|
WO2018226992A1
(en)
|
2017-06-07 |
2018-12-13 |
Adrx, Inc. |
Tau aggregation inhibitors
|
|
FI3642202T3
(fi)
|
2017-06-22 |
2023-03-01 |
|
Dihydro-pyrrolo-pyridiinijohdannaisia
|
|
US11530257B2
(en)
*
|
2017-06-29 |
2022-12-20 |
The Trustees Of Columbia University In The City Of New York |
Chimeric antibodies for treatment of amyloid deposition diseases
|
|
WO2019014768A1
(en)
|
2017-07-18 |
2019-01-24 |
The University Of British Columbia |
ANTI-BETA-AMYLOID ANTIBODY
|
|
US12286469B2
(en)
|
2017-07-18 |
2025-04-29 |
The University Of British Columbia |
Humanized antibodies binding to amyloid-beta (A-beta)
|
|
JP7368856B2
(ja)
|
2017-07-25 |
2023-10-25 |
トゥルーバインディング，インコーポレイテッド |
Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
|
|
US11382974B2
(en)
|
2017-08-01 |
2022-07-12 |
The Trustees Of Columbia University In The City Of New York |
Methods and compositions for treatment of amyloid deposition diseases
|
|
EP3668886A2
(en)
|
2017-08-18 |
2020-06-24 |
Adrx, Inc. |
Tau aggregation peptide inhibitors
|
|
MX2020007266A
(es)
|
2017-09-26 |
2020-09-07 |
Cero Therapeutics Inc |
Moleculas del receptor quimerico de engullido y metodos de uso.
|
|
EP3461819B1
(en)
|
2017-09-29 |
2020-05-27 |
Probiodrug AG |
Inhibitors of glutaminyl cyclase
|
|
WO2019074840A1
(en)
*
|
2017-10-09 |
2019-04-18 |
Keith Black |
COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOID RELATED DISEASES
|
|
CA3094366A1
(en)
|
2018-03-23 |
2019-09-26 |
Pfizer Inc. |
Piperazine azaspiro derivatives
|
|
EP3774865A1
(en)
|
2018-03-28 |
2021-02-17 |
Cero Therapeutics, Inc. |
Cellular immunotherapy compositions and uses thereof
|
|
US20210015865A1
(en)
|
2018-03-28 |
2021-01-21 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
|
|
WO2019226690A1
(en)
*
|
2018-05-21 |
2019-11-28 |
New York University |
Treatment of melanoma brain metastasis by inhibition of amyloid precursor protein cleavage
|
|
US12018069B2
(en)
|
2018-06-28 |
2024-06-25 |
The Trustees Of Columbia University In The City Of New York |
Methods and compositions for imaging amyloid deposits
|
|
JP7611149B2
(ja)
|
2018-10-04 |
2025-01-09 |
ユニバーシティ オブ ロチェスター |
血漿浸透圧を操作することによるグリンパティック送達の改善
|
|
CN113227131B
(zh)
|
2018-12-20 |
2025-03-04 |
豪夫迈·罗氏有限公司 |
经修饰的抗体Fc及其使用方法
|
|
FR3091999A1
(fr)
*
|
2019-01-25 |
2020-07-31 |
Mexbrain |
Dispositif d’extraction conjointe d’un cation métallique et d’une molécule cible
|
|
CN116063505B
(zh)
|
2019-01-30 |
2024-05-03 |
真和制药有限公司 |
抗gal3抗体及其用途
|
|
CA3154522A1
(en)
|
2019-10-15 |
2021-04-22 |
Christopher Carl Frye |
Recombinantly engineered, lipase/esterase-deficient mammalian cell lines
|
|
US12281166B2
(en)
|
2020-05-26 |
2025-04-22 |
Truebinding, Inc. |
Methods of treating inflammatory diseases by blocking Galectin-3
|
|
WO2022020680A1
(en)
|
2020-07-23 |
2022-01-27 |
Othair Prothena Limited |
Anti-abeta antibodies
|
|
TWI843040B
(zh)
|
2021-01-11 |
2024-05-21 |
美商美國禮來大藥廠 |
抗N3pGlu類澱粉β抗體及其用途
|
|
EP4297868A4
(en)
|
2021-02-23 |
2025-01-08 |
Hoth Therapeutics, Inc. |
USE OF APREPITANT TO TREAT ALZHEIMER'S
|
|
TW202300517A
(zh)
|
2021-03-12 |
2023-01-01 |
美商美國禮來大藥廠 |
抗類澱粉β抗體及其用途
|
|
TW202300518A
(zh)
|
2021-03-12 |
2023-01-01 |
美商美國禮來大藥廠 |
抗N3pGlu類澱粉β抗體及其用途
|
|
WO2022251048A1
(en)
|
2021-05-24 |
2022-12-01 |
Eli Lilly And Company |
Anti-amyloid beta antibodies and uses thereof
|
|
US20250064417A1
(en)
|
2022-02-03 |
2025-02-27 |
Eli Lilly And Company |
Regional tau imaging for diagnosing and treating alzheimer's disease
|
|
WO2025032070A1
(en)
|
2023-08-09 |
2025-02-13 |
F. Hoffmann-La Roche Ag |
Anti-a-beta protein antibodies, methods and uses thereof
|
|
WO2025145091A1
(en)
|
2023-12-29 |
2025-07-03 |
Pfizer Inc. |
Crystalline forms of a muscarinic m4 receptor modulator and methods of treating diseases
|